AJCN North Carolina Research Campus
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dierkes, J.
Right arrow Articles by Boeing, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dierkes, J.
Right arrow Articles by Boeing, H.
Agricola
Right arrow Articles by Dierkes, J.
Right arrow Articles by Boeing, H.
American Journal of Clinical Nutrition, Vol. 86, No. 1, 214-220, July 2007
© 2007 American Society for Nutrition

ORIGINAL RESEARCH COMMUNICATION

Plasma pyridoxal-5-phosphate and future risk of myocardial infarction in the European Prospective Investigation into Cancer and Nutrition Potsdam cohort1,2,3

Jutta Dierkes, Cornelia Weikert, Kerstin Klipstein-Grobusch, Sabine Westphal, Claus Luley, Matthias Möhlig, Joachim Spranger and Heiner Boeing

1 From the Institute of Clinical Chemistry and Biochemistry, University Hospital Magdeburg, Magdeburg, Germany (JD, SW, and CL); the Department of Epidemiology, German Institute of Human Nutrition, Nuthetal, Germany (CW, KK-G, and HB); the School of Public Health, University of the Witwatersrand, Parktown, South Africa (KK-G); and the Department of Clinical Nutrition, German Institute of Human Nutrition, Nuthetal, Germany (MM and JS)

2 Supported by the Federal Ministry of Education and Research (BMBF; research grant 0312750B).

3 Reprints not available. Address correspondence to J Dierkes, Institute of Clinical Chemistry, University Hospital Magdeburg, Leipziger Str. 44, D-39120 Magdeburg, Germany. E-mail: jutta.dierkes{at}medizin.uni-magdeburg.de.


   ABSTRACT
TOP
 ABSTRACT
INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
Background: Retrospective studies indicate that low concentrations of plasma pyridoxal-5-phosphate (PLP) are associated with cardiovascular events; however, few prospective studies of this issue have been conducted.

Objective: We therefore investigated whether PLP concentrations are independently associated with myocardial infarction (MI) in the European Investigation into Cancer and Nutrition (EPIC) Potsdam Study.

Design: After exclusion of prevalent MI or stroke, incident cases of MI were identified among 26 761 participants (aged 35–65 y at baseline). The current analysis is based on a nested case-cohort study consisting of a control group of 810 subjects without MI or stroke at baseline and a case group of 148 subjects who had an MI during a mean follow-up period of 6.0 ± 1.5 y. Cox proportional hazard models were used to evaluate the association between plasma PLP and risk of MI.

Results: In the age- and sex-adjusted analysis, subjects in the highest quintile of PLP had a significantly reduced risk of MI (hazard ratio: 0.50; 95% CI: 0.29, 0.83). Adjustment for either low-grade inflammation or smoking diminished this association. When both low-grade inflammation and smoking were adjusted for, the association was abolished. In addition, adjustment for established risk factors also abolished the association between PLP and risk of MI.

Conclusion: These findings from a prospective German cohort study suggest that PLP is not independently associated with risk of MI.

Key Words: Cardiovascular disease • epidemiology • vitamin B-6 • inflammation • smoking


   INTRODUCTION
TOP
 ABSTRACT
 INTRODUCTION
SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 
There is increasing interest in B vitamins as risk factors for cardiovascular disease (CVD) because of the recognition of homocysteine as a potential risk factor for CVD (1), and it has been recognized that subnormal, but not necessarily deficient, concentrations of vitamins can be associated with an increased risk of CVD (2). Of the vitamins of interest, vitamin B-6 has received much attention because of its involvement in homocysteine metabolism, polyunsaturated fatty acid and lipid metabolism, and protein metabolism. Furthermore, vitamin B-6 was shown to inhibit platelet aggregation and endothelial cell proliferation, which suggests that it has an antithrombotic effect (3). Epidemiologic evidence for a potential protective action of vitamin B-6 first emerged from small studies in patients after a myocardial infarction (MI) (4) and in mostly retrospective case-control studies involving patients with coronary, cerebral, or peripheral atherosclerotic disease (5–11). In most of those retrospective studies an association was found between low plasma pyridoxal-5-phosphate (PLP) and CVD. In addition, 2 corresponding prospective studies were published: one involved men participating in the Physicians' Health Study (12), the other men and women of the Atherosclerosis Risk Factors in the Community (ARIC) study (13). These prospective studies reported divergent results for the association between PLP and CVD. Although in the Physicians' Health Study the association was no longer significant after adjustment for established CVD risk factors, in the ARIC study multiple adjustment did not alter the results. Regardless of the study design, all studies so far investigated the risk of CVD associated with the plasma PLP concentration as a measure of the nutritional status of vitamin B-6. Subsequently, the interpretation of low plasma PLP became more difficult, because low-grade inflammation was found to be associated with low plasma PLP.

Friso et al (14) showed that in the Framingham cohort chronic inflammation modulated plasma PLP concentrations. Despite similar vitamin B-6 intake, the plasma PLP concentrations were significantly lower in subjects with C-reactive protein (CRP) > 6 mg/L than subjects with CRP concentrations < 6 mg/L. This observation was confirmed in healthy elderly subjects in the United Kingdom (15), patients with rheumatoid arthritis (16), inflammatory bowel disease (17), and type 2 diabetes (18). During the past decade the view on chronic inflammation as a cardiovascular disease risk factor changed considerably because of the discovery that chronic low-grade chronic inflammation is present in patients at high risk of CVD or patients with CVD (19, 20). The diagnosis of chronic low-grade inflammation became only possible after the introduction of measurement of highly sensitive CRP (hsCRP) as a sensitive laboratory method (21, 22). These findings question in particular the results of the retrospective studies on low plasma PLP and risk of CVD. So far, neither of the prospective studies and only 2 of the retrospective studies were adjusted for hsCRP (10, 11). Although Friso et al (10) observed a significant association between low plasma PLP and CVD both before and after adjustment for CRP in patients with coronary artery disease, Dierkes et al (11) reported that the association disappeared completely after adjustment for hsCRP in a study involving women with prior MI or acute coronary syndrome.

There is therefore a need for prospective studies on the association between plasma PLP and cardiovascular disease risk that would take first markers of inflammation into account in the statistical procedure, and, second, investigate the associations of plasma PLP with other cardiovascular disease risk factors. In this analysis, we present data from the European Prospective Investigation into Cancer and Nutrition (EPIC) Potsdam cohort in Germany, with respect to the association of plasma PLP and future risk of MI.


   SUBJECTS AND METHODS
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
RESULTS
 DISCUSSION
 REFERENCES
 
Study population
The EPIC Potsdam cohort was recruited between August 1994 and September 1998 as part of the multicenter EPIC study. Details of this cohort as a part of the German study population were published elsewhere (23). Briefly, women aged 35–65 y and men aged 40–65 y were recruited at random from the general population. In total, 27 548 subjects (16 644 women and 10 904 men) underwent the baseline examination, including standardized blood pressure measurements, measurements of weight and height, self-administered questionnaires on diet and lifestyle, computer-guided interviews, and blood sampling. The study was approved by the Ethics Committee of Federal State Brandenburg, Germany, and written informed consent was obtained from all participants.

After the exclusion of subjects with a history of MI and stroke at baseline, we identified 156 participants who had a MI during follow-up until 30 April 2004. For the purpose of biomarker measurement a study in a case-cohort design was established (24, 25). In this study type, a random subcohort of the total baseline cohort is drawn as a reference group. If a subset member develops a disease of interest during follow-up, this person is also treated as a case and contributes to the exposure distribution among the cases (24). For the current analyses, a subcohort comprising 851 subjects free of MI and stroke at baseline was randomly drawn from the EPIC-Potsdam cohort (n = 26 761). Five incident MIs occurred among these subcohort members. For the present analyses we excluded 8 cases and 36 noncases without sufficient plasma or DNA samples, leaving a final case-cohort sample of 148 cases and a subcohort of 815 subjects, including 810 noncases and 5 cases.

Baseline examinations
A total of 30 mL venous blood was collected at baseline from each study participant during examinations for the cohort study at the Potsdam center. The plasma was separated from the blood cells within 2 h, and all samples were frozen at –80 °C until the time of analysis.

Standardized anthropometric measurements were performed by trained personnel (26). The body mass index (BMI; in kg/m2) was calculated. Lifestyle characteristics, including regular physical exercise and smoking history, were documented by trained interviewers during a computer-guided interview. Smoking status was expressed as "current smoker," "nonsmoker," and "former smoker." Physical exercise was defined as the mean time spent on sporting activities during the summer and winter seasons (in h/wk). For the assessment of their medical history, the participants answered questions about past diseases and regular use of medication.

With the use of oscillometric devices (BOSO-Oscillomat; Bosch & Sohn, Jungingen, Germany), presence of hypertension was defined on the basis of the mean values of the second and third blood pressure measurements during baseline examinations as systolic blood pressure ≥ 140 mm Hg or diastolic blood pressure ≥ 90 mm Hg or from the subjects' reports, disease-specific medication, or verification from medical records. Definition of diabetes was based on subjects' reports or disease-specific medication or verification from medical records.

At baseline, the dietary habits during the preceding year were assessed by a validated self-administered food-frequency questionnaire (27, 28). The food-frequency questionnaire included questions on frequency and portion size of 146 individual food items and on regular use of vitamin supplements (during the previous year); it was described in detail elsewhere (29).

Definition of MI
Every 2–3 y, the participants were asked to complete a mailed follow-up questionnaire that included sections about self-reported MI. Potential incident MIs were verified from medical records or death certificates, applying the criteria based on the WHO-MONICA (MONItoring CArdiovascular disease) study (Internet: http://www.ktl.fi/publications/monica/manual/part4/iv-1.htm). Thus, cases were defined as incident MIs, according to codes I21.0–I21.9 from the 10th revision of the International Classification of Diseases, occurring between the baseline examination and 30 April 2004.

Blood measurements
Blood samples of selected study subjects were dispatched to the Institute of Clinical Chemistry on dry ice to be analyzed for PLP, folate, and creatinine. Plasma folate was measured with the use of a commercial test assay (Roche Diagnostics, Mannheim, Germany). PLP was measured by HPLC with fluorescence detection with the use of a commercial test kit (Immundiagnostik GmbH, Bensheim, Germany). The normal range of this assay is >18.2 nmol/L. Creatinine was measured enzymatically on a random access autoanalyzer (Roche Diagnostics). Plasma homocysteine was measured by HPLC with fluorescence detection (30). Blood lipids and hsCRP were measured at the German Institute of Human Nutrition Potsdam-Rehbrücke. Total and HDL cholesterol and hsCRP were measured with the use of standard methods with reagents from Horiba ABX (Shefford, United Kingdom). The intraassay CVs were 0.9% (total cholesterol), 1.2% (HDL cholesterol), and 2.6% (hsCRP), and the interassay CVs were 4.7%, 5.2%, and 7.9%, respectively.

Statistics
The statistical analysis was performed with the use of SAS software package, release 9.1 (SAS Institute, Cary, NC). All tests were 2-sided, P < 0.05 as the significance threshold. Associations of PLP with the plasma concentrations of hsCRP, HDL cholesterol, creatinine, folate, and cobalamin and also with dietary variables such as intakes of vitamin B-6 and folate were studied by calculating Spearman ñ coefficients. The effect of smoking on PLP was tested with the use of the general linear model with 3 smoking categories. Cox proportional hazard regression analysis was used for the examination of the relation between PLP and risk of MI. Age was the underlying time variable in the counting process, with entry defined as the subjects' age at the time of recruitment and exit defined as age at the diagnosis of MI or censoring. As suggested by Prentice (24), the Cox models were modified to account for the case-cohort design. With the Prentice method, participants within the subcohort are given a weight of 1 at all times, whereas cases outside the subcohort have a weight of 1 at time of event and have weight of 0 at all other times (24). Hazard rate ratios were calculated for quintiles of PLP. Quintiles of PLP plasma concentrations are based on distribution of the subcohort. The lowest quintile was used as the reference category. The association of PLP with risk of MI was first calculated after adjustment for age and for sex. As a control for the known association of hsCRP on PLP, hsCRP was first introduced into the age- and sex-adjusted model. Because smoking also showed a significant association with PLP, a model containing age, sex, and smoking in 3 categories (never smoked, former smoker, current smoker) was constructed. In addition, a model of age, sex, and the ratio of total cholesterol to HDL cholesterol (total cholesterol:HDL cholesterol) was constructed. The effect of multiple risk factors on the association of PLP with risk of MI was then tested in a model consisting of age and sex, hsCRP, smoking, and total cholesterol:HDL cholesterol. To this model, other known risk factors for ischemic heart disease were then added, including calculated alcohol intake, regular exercise (<2 h/wk, >2 h/wk), educational level (university degree, no university degree), and in addition BMI, hypertension, and diabetes mellitus. Tests for trends across increasing quintiles of PLP concentration were conducted by using the quintile number as a continuous variable in Cox proportional hazard models.

To evaluate putative interactions between PLP and important confounders, multiplicative interaction terms of PLP and sex, PLP and smoking, and PLP and hsCRP were included and tested in the fully adjusted Cox regression model. Furthermore, we investigated whether the effect of PLP on incidence of MI was changing over time, applying the test for proportionality assumption of the Cox model. The proportionality assumption was not rejected in our analyses, suggesting that the influence of PLP on incidence of MI did not change over time.


   RESULTS
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
DISCUSSION
 REFERENCES
 
Subject characteristics
The current analysis is based on a nested case-cohort study consisting of 815 subjects in a subcohort of the EPIC Potsdam study and 148 subjects who had an MI during a mean follow-up of 6.0 ± 1.5 y. One hundred eleven cases were nonfatal and the remaining 37 were fatal.

Selected baseline characteristics according to PLP quintiles are presented in Table 1Go. Subjects with higher PLP concentrations were less likely to be men, to be current smokers, or to have a history of hypertension or diabetes at baseline than were subjects with low PLP concentrations. The plasma PLP at baseline correlated significantly with vitamin B-6 intake (r = 0.15, n = 958, P < 0.001), hsCRP (r = –0.25, n = 958, P < 0.001), homocysteine (r = –0.11, n = 958, P < 0.001), both folate intake (r = 0.17, n = 958, P < 0.001) and plasma folate (r = 0.31, n = 958, P < 0.001), and HDL cholesterol (r = 0.10, n = 958, P < 0.01). The association between PLP and hsCRP remained unchanged when 4 subjects with CRP > 20 mg/L (indicating acute inflammation) were excluded. Smoking exhibited a significant effect on plasma PLP, with lower concentrations in current smokers compared with former smokers or never smokers (Table 2Go).


View this table:
[in this window]
[in a new window]

  		TABLE 1. Baseline characteristics of study participants in the European Investigation into Cancer and Nutrition (EPIC) Potsdam case-cohort study (n = 958) according to quintile (Q) of plasma pyridoxal-5-phosphate (PLP)1

 

View this table:
[in this window]
[in a new window]

  		TABLE 2. Association between smoking and plasma pyridoxal-5-phosphate (PLP)1

 
PLP and risk of MI
In the Cox regression model adjusted for age and sex, higher quintiles of plasma PLP were significantly associated with a lower risk of MI (Table 3Go). The relative risk for subjects in the fifth quintile for plasma PLP was 0.50 (95% CI: 0.29, 0.83), compared with subjects with plasma PLP in the lowest quintile. This association was substantially weakened after adjustment for either hsCRP or smoking or for total cholesterol:HDL cholesterol. When the model was adjusted for the combination of these risk factors, the association of PLP and risk of MI was completely abolished.


View this table:
[in this window]
[in a new window]

  		TABLE 3. Hazard ratios (and 95% CIs) by plasma pyridoxal-5-phosphate (PLP) quintile (Q) for 148 cases of myocardial infarction and 810 control subjects from the European Investigation into Cancer and Nutrition (EPIC) Potsdam cohort1

 
Further adjustment for other factors known to be associated to coronary risk, such as alcohol intake, physical activity, educational level, hypertension, diabetes, or BMI did not change this result substantially (Table 3Go). Further adjustment for homocysteine did not change this result substantially (data not shown). When the Cox analysis was performed for PLP tertiles or quartiles, the associations between PLP and risk of MI became weaker. In fact, the association between tertiles or quartiles of PLP and risk of MI disappeared already after adjustment for hsCRP alone (data not shown). We did not observe any statistically significant interaction between PLP and sex, PLP and smoking, or PLP and hsCRP (data not shown).

PLP compared with other risk factors
In the fully adjusted model, established risk factors such as total cholesterol:HDL cholesterol, hypertension at baseline, smoking, and hsCRP still predicted MI. The hazard ratios were 1.66 (95% CI: 1.42, 1.96) for one unit increase of the total cholesterol:HDL cholesterol, 2.02 (95% CI: 1.31, 3.11) for hypertension at baseline, 3.03 (95% CI: 2.03, 4.53) for smoking, and 1.08 (95% CI: 1.01, 1.15) for one unit increase of hsCRP.


   DISCUSSION
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
REFERENCES
 
The present work is the first European prospective study on the association between plasma PLP and cardiovascular disease risk, after the publication of numerous retrospective studies and 2 American studies with nested case-control design (12, 13). The principal finding of the present nested case-cohort study is that the plasma PLP was not associated with future MI in a cohort of German middle-aged men and women healthy at the time of entry into the study and after adjustment for known cardiovascular disease risk factors. This disagrees with the findings reported by other groups in studies with retrospective design (5, 8, 10) and with studies that also followed a nested case-control design (13), but it is in accord with earlier, retrospective studies (6, 7, 11), including our own, and with one of the prospective studies (12).

The main reason to doubt the existence of a causal association between PLP and CVD was the increasing evidence of an effect of the inflammatory response on plasma PLP. This was first observed in elderly British subjects (15) and in British children and adolescents (31), then in the Framingham cohort (14), and in persons with type 2 diabetes with nephropathy (18), but not in a random middle-aged subsample of the ARIC study (32). The association persisted in the studies even after the exclusion of subjects with acute inflammatory reactions. It seems that this result is independent of the manner of PLP quantification: by HPLC or by the radioenzymatic tyrosine decarboxylase method.

With the exception of Friso et al (10), most previous studies on PLP as a risk factor for CVD made no adjustment for the acute-phase response. However, higher CRP concentrations are usually observed in the cases included both in retrospective and prospective studies (10, 11, 19, 20). This evidently may influence the PLP concentration and may be able to imitate a strong association between PLP and CVD. Although we observed a strong inverse association between plasma PLP and hsCRP, adjustment for hsCRP alone did not abolish the association between PLP and risk of MI, a finding in line with Friso et al (10). In most studies, more patients with MI than control subjects usually have a history of smoking or are current smokers. We observed a strong effect of smoking on plasma PLP, although the association between PLP and future risk of MI was not abolished by introducing smoking alone into the model. Lower plasma PLP concentrations in smokers were reported earlier (33), but the consequences on the association between plasma PLP and risk of MI have not been studied in detail. However, when hsCRP and smoking were introduced into the Cox regression model, the association of plasma PLP and MI was abolished (data not shown).

We also observed an association between HDL-cholesterol and plasma PLP concentrations, especially in men. To our knowledge, no studies in the general population reported this association earlier. This is therefore an interesting observation that deserves future investigations.

The idea that high plasma PLP concentrations may be cardioprotective is indeed supported by some evidence derived from biochemical studies. PLP is a coenzyme of numerous biological pathways in the carbohydrate, amino acid, protein, and lipid metabolism. This offers a great number of mechanisms that may contribute to an antiatherogenic action of PLP. Among these, PLP is a coenzyme of d6-desaturase, involved in the metabolism of polyunsaturated fatty acids (34, 35), and a coenzyme of cystathionine-ß-synthase involved in methionine, homocysteine, and cysteine metabolism (36). Furthermore, it can occupy glycoprotein IIb or IIIa, a major receptor on platelets responsible for platelet aggregation (3), and it was shown that PLP can inhibit proliferation of endothelial cells (37).

Epidemiologic studies on vitamin B-6 intake, however, are also inconsistent about whether a higher intake of vitamin B-6 is antiatherogenic. In the Nurses' Health Study, a higher intake of vitamin B-6 was associated with a reduced risk of MI (38). However, the effect was mostly due to the use of supplements and was strongly related and indistinguishable from folic acid intake from supplements, making interpretation of the results difficult. In the Health Professionals Follow-Up Study vitamin B-6 intake was not related with future strokes (39). In the ARIC study, the dietary intake of vitamin B-6 was not different between cases and control subjects (13).

It was proposed that the effect of inflammation on PLP is tissue specific, and, indeed, studies in critically ill subjects (40) and in patients with rheumatoid arthritis (41) showed low plasma PLP in the patients. In erythrocytes, however, the PLP content was similar to that in control subjects. A fall in plasma PLP but not in erythrocyte PLP was observed earlier in patients after MI (42). Moreover, in rats with chronic or acute inflammation, the plasma PLP and the liver PLP were reduced, whereas muscle PLP and urinary pyridoxic acid excretion were no different from those in control animals (41). Theoretically, measurement of the erythrocyte aspartate aminotransferase activation coefficient offers another way of determining the vitamin B-6 status in humans, but in epidemiologic studies the preanalytic requirements for this method are unrealistic. This may also limit the use of erythrocyte PLP measurements, because the availability of whole blood or packed erythrocytes in epidemiologic blood banks is limited. Finally, it was shown that plasma PLP reflects the vitamin B-6 status in the liver (43). At present, it must be concluded that, although the determination of plasma PLP is obviously not an optimized method for vitamin B-6 measurements, it is the only one that is practical in large-scale cohort studies.

The EPIC Potsdam cohort has several strengths and a few limitations. The main strengths are obviously the prospective study design, the blinded analysis, and the availability of extended data of participants, allowing a full adjustment for other risk factors. All incident cases were verified by the patients' medical records or death certificates (29, 44). The main limitation is the relatively small number of cases with MI, which is probably due to the oversampling of women in the cohort and to the relatively short time of follow-up. However, we believe that the conclusions drawn are valid although the number of cases is relatively low. Established risk factors such as total cholesterol:HDL cholesterol, hypertension at baseline, smoking, or hsCRP remained predictive for MI even in the fully adjusted model.

In conclusion, our results suggest that the association of plasma PLP with cardiovascular disease risk is mainly explained by other risk factors that lead to low plasma PLP concentrations. In particular, high hsCRP (a measure of inflammation) and smoking had an association with low plasma PLP concentrations.

Low plasma PLP concentrations in high-risk patients obviously do not primarily indicate a vitamin B-6 deficiency, but they appear to reflect low-grade inflammation and smoking that are more often present in high-risk patients. Thus, low plasma PLP concentrations are not an independent risk factor for MI. At present it is debatable whether the measurement of PLP concentrations in whole blood would confirm this association. In future epidemiologic studies other means of vitamin B-6 status (both measurements of plasma PLP and whole-blood PLP, or plasma or urinary pyridoxic acid), and major confounders should be used if possible to clarify the association between vitamin B-6 and CVD.


   ACKNOWLEDGMENTS
 
We thank Elke Hinze for the laboratory measurements, Ellen Kohlsdorf and Wolfgang Bernigau for data management, Wolfgang Fleischhauer for ascertaining the MI cases, and Kurt Hoffmann for assistance with the statistics.

The author's responsibilities were as follows—JD and CW: wrote the first draft of the manuscript, conducted the statistical analysis, and contributed equally; JD, SW, CL, MM, and JS: performed the laboratory measurements; HB: planned and conducted the EPIC-Potsdam Study; KK-G: contributed to the study design, acquisition, and interpretation of data in the EPIC-Potsdam Study. All authors critically revised the manuscript for important intellectual content. None of the authors had a conflict of interest in relation to this study.


   REFERENCES
TOP
 ABSTRACT
 INTRODUCTION
 SUBJECTS AND METHODS
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. Fairfield KM, Fletcher RH. Vitamins for chronic disease prevention in adults: scientific review. JAMA 2002;287:3116–26.[Abstract/Free Full Text]
  2. Yates AA, Schlicker SA, Suitor CW. Dietary Reference Intakes: the new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J Am Diet Assoc 1998;98:699–706.[Medline]
  3. Chang SJ, Chang CN, Chen CW. Occupancy of glycoprotein IIb/IIIa by B-6 vitamers inhibits human platelet aggregation. J Nutr 2002;132:3603–6.[Abstract/Free Full Text]
  4. Serfontein WJ, Ubbink JB, De Villiers LS, Rapley CH, Becker PJ. Plasma pyridoxal-5-phosphate level as risk index for coronary artery disease. Atherosclerosis 1985;55:357–61.[Medline]
  5. Robinson K, Arheart K, Refsum H, et al. Low circulating folate and vitamin B6 concentrations: risk factors for stroke, peripheral vascular disease, and coronary artery disease. European COMAC Group. Circulation 1998;97:437–43.[Abstract/Free Full Text]
  6. Verhoef P, Stampfer MJ, Buring JE, et al. Homocysteine metabolism and risk of myocardial infarction: relation with vitamins B6, B12, and folate. Am J Epidemiol 1996;143:845–59.[Abstract/Free Full Text]
  7. Verhoef P, Kok FJ, Kruyssen DA, et al. Plasma total homocysteine, B vitamins, and risk of coronary atherosclerosis. Arterioscler Thromb Vasc Biol 1997;17:989–95.[Abstract/Free Full Text]
  8. Robinson K, Mayer EL, Miller DP, et al. Hyperhomocysteinemia and low pyridoxal phosphate. Common and independent reversible risk factors for coronary artery disease. Circulation 1995;92:2825–30.[Abstract/Free Full Text]
  9. Kelly PJ, Shih VE, Kistler JP, et al. Low vitamin B6 but not homocyst(e)ine is associated with increased risk of stroke and transient ischemic attack in the era of folic acid grain fortification. Stroke 2003;34:e51–4.[Abstract/Free Full Text]
  10. Friso S, Girelli D, Martinelli N, et al. Low plasma vitamin B-6 concentrations and modulation of coronary artery disease risk. Am J Clin Nutr 2004;79:992–8.[Abstract/Free Full Text]
  11. Dierkes J, Hoffmann K, Klipstein-Grobusch K, et al. Low plasma pyridoxal-5phosphate and cardiovascular disease risk in women: results from the Coronary Risk Factors for Atherosclerosis in Women Study. Am J Clin Nutr 2005;81:725–7; author reply 727–8.[Free Full Text]
  12. Chasan-Taber L, Selhub J, Rosenberg IH, et al. A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr 1996;15:136–43.[Abstract]
  13. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 1998;98:204–10.[Abstract/Free Full Text]
  14. Friso S, Jacques PF, Wilson PW, Rosenberg IH, Selhub J. Low circulating vitamin B(6) is associated with elevation of the inflammation marker C-reactive protein independently of plasma homocysteine levels. Circulation 2001;103:2788–91.[Abstract/Free Full Text]
  15. Bates CJ, Pentieva KD, Prentice A, Mansoor MA, Finch S. Plasma pyridoxal phosphate and pyridoxic acid and their relationship to plasma homocysteine in a representative sample of British men and women aged 65 years and over. Br J Nutr 1999;81:191–201.[Medline]
  16. Roubenoff R, Roubenoff RA, Selhub J, et al. Abnormal vitamin B6 status in rheumatoid cachexia. Association with spontaneous tumor necrosis factor alpha production and markers of inflammation. Arthritis Rheum 1995;38:105–9.[Medline]
  17. Saibeni S, Cattaneo M, Vecchi M, et al. Low vitamin B(6) plasma levels, a risk factor for thrombosis, in inflammatory bowel disease: role of inflammation and correlation with acute phase reactants. Am J Gastroenterol 2003;98:112–7.[Medline]
  18. Friedman AN, Hunsicker LG, Selhub J, Bostom AG. Clinical and nutritional correlates of C-reactive protein in type 2 diabetic nephropathy. Atherosclerosis 2004;172:121–5.[Medline]
  19. Ridker PM, Buring JE, Shih J, Matias M, Hennekens CH. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998;98:731–3.[Abstract/Free Full Text]
  20. Ridker PM, Hennekens CH, Buring JE, Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000;342:836–43.[Abstract/Free Full Text]
  21. Rifai N, Tracy RP, Ridker PM. Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999;45:2136–41.[Abstract/Free Full Text]
  22. Ockene IS, Matthews CE, Rifai N, Ridker PM, Reed G, Stanek E. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem 2001;47:444–50.[Abstract/Free Full Text]
  23. Boeing H, Korfmann A, Bergmann MM. Recruitment procedures of EPIC-Germany. European Investigation into Cancer and Nutrition. Ann Nutr Metab 1999;43:205–15.[Medline]
  24. Prentice R. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 1986;73:1–11.[Abstract/Free Full Text]
  25. Miettinen O. Design options in epidemiologic research. An update. Scand J Work Environ Health 1982;8(suppl):7–14.
  26. Klipstein-Grobusch K, Georg T, Boeing H. Interviewer variability in anthropometric measurements and estimates of body composition. Int J Epidemiol 1997;26(suppl):S174–80.[Abstract/Free Full Text]
  27. Bohlscheid-Thomas S, Hoting I, Boeing H, Wahrendorf J. Reproducibility and relative validity of energy and macronutrient intake of a food frequency questionnaire developed for the German part of the EPIC project. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 1997;26(suppl):S71–81.[Abstract/Free Full Text]
  28. Boeing H, Bohlscheid-Thomas S, Voss S, Schneeweiss S, Wahrendorf J. The relative validity of vitamin intakes derived from a food frequency questionnaire compared to 24-hour recalls and biological measurements: results from the EPIC pilot study in Germany. European Prospective Investigation into Cancer and Nutrition. Int J Epidemiol 1997;26(suppl):S82–90.[Abstract/Free Full Text]
  29. Drogan D, Klipstein-Grobusch K, Dierkes J, Weikert C, Boeing H. Dietary intake of folate equivalents and risk of myocardial infarction in the European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam study. Public Health Nutr 2006;9:465–71.[Medline]
  30. Dierkes J, Jeckel A, Ambrosch A, Westphal S, Luley C, Boeing H. Factors explaining the difference of total homocysteine between men and women in the European Investigation Into Cancer and Nutrition Potsdam study. Metabolism 2001;50:640–5.[Medline]
  31. Bates CJ, Pentieva KD, Prentice A. An appraisal of vitamin B6 status indices and associated confounders, in young people aged 4–18 years and in people aged 65 years and over, in two national British surveys. Public Health Nutr 1999;2:529–35.[Medline]
  32. Folsom AR, Desvarieux M, Nieto FJ, Boland LL, Ballantyne CM, Chambless LE. B vitamin status and inflammatory markers. Atherosclerosis 2003;169:169–74.[Medline]
  33. Walmsley CM, Bates CJ, Prentice A, Cole TJ. Relationship between cigarette smoking and nutrient intakes and blood status indices of older people living in the UK: further analysis of data from the National Diet and Nutrition Survey of people aged 65 years and over, 1994/95. Public Health Nutr 1999;2:199–208.[Medline]
  34. Tsuge H, Hotta N, Hayakawa T. Effects of vitamin B-6 on (n–3) polyunsaturated fatty acid metabolism. J Nutr 2000;130(suppl):333S–4S.[Medline]
  35. Cabrini L, Bochicchio D, Bordoni A, Sassi S, Marchetti M, Maranesi M. Correlation between dietary polyunsaturated fatty acids and plasma ho-mocysteine concentration in vitamin B6-deficient rats. Nutr Metab Cardiovasc Dis 2005;15:94–9.[Medline]
  36. Ubbink JB, van der Merwe A, Delport R, et al. The effect of a subnormal vitamin B-6 status on homocysteine metabolism. J Clin Invest 1996;98:177–84.[Medline]
  37. Matsubara K, Matsumoto H, Mizushina Y, Lee JS, Kato N. Inhibitory effect of pyridoxal 5-phosphate on endothelial cell proliferation, replicative DNA polymerase and DNA topoisomerase. Int J Mol Med 2003;12:51–5.[Medline]
  38. Rimm EB, Willett WC, Hu FB, et al. Folate and vitamin B6 from diet and supplements in relation to risk of coronary heart disease among women. JAMA 1998;279:359–64.[Abstract/Free Full Text]
  39. He K, Merchant A, Rimm EB, et al. Folate, vitamin B6, and B12 intakes in relation to risk of stroke among men. Stroke 2004;35:169–74.[Abstract/Free Full Text]
  40. Talwar D, Quasim T, McMillan DC, Kinsella J, Williamson C, O'Reilly DS. Pyridoxal phosphate decreases in plasma but not erythrocytes during systemic inflammatory response. Clin Chem 2003;49:515–8.[Free Full Text]
  41. Chiang EP, Smith DE, Selhub J, Dallal G, Wang YC, Roubenoff R. Inflammation causes tissue-specific depletion of vitamin B6. Arthritis Res Ther 2005;7:R1254–62.[Medline]
  42. Vermaak WJ, Barnard HC, Van Dalen EM, Potgieter GM, Van Jaarsveld H, Myburgh SJ. Compartmentalization of pyridoxal-5-phosphate during the acute phase of myocardial infarction. Klin Wochenschr 1988;66:428–33.[Medline]
  43. Lumeng L, Lui A, Li TK. Plasma content of B6 vitamers and its relationship to hepatic vitamin B6 metabolism. J Clin Invest 1980;66:688–95.[Medline]
  44. Weikert C, Hoffmann K, Dierkes J, et al. A homocysteine metabolism-related dietary pattern and the risk of coronary heart disease in two independent German study populations. J Nutr 2005;135:1981–8.[Abstract/Free Full Text]
Received for publication September 29, 2006. Accepted for publication March 5, 2007.




This article has been cited by other articles:


Home page
 JAMAHome page
M. Ebbing, O. Bleie, P. M. Ueland, J. E. Nordrehaug, D. W. Nilsen, S. E. Vollset, H. Refsum, E. K. Ringdal Pedersen, and O. Nygard
Mortality and Cardiovascular Events in Patients Treated With Homocysteine-Lowering B Vitamins After Coronary Angiography: A Randomized Controlled Trial
JAMA, August 20, 2008; 300(7): 795 - 804.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Clin. Nutr.Home page
A. T Vasilaki, D. C McMillan, J. Kinsella, A. Duncan, D. S. J O'Reilly, and D. Talwar
Relation between pyridoxal and pyridoxal phosphate concentrations in plasma, red cells, and white cells in patients with critical illness
Am. J. Clinical Nutrition, July 1, 2008; 88(1): 140 - 146.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dierkes, J.
Right arrow Articles by Boeing, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dierkes, J.
Right arrow Articles by Boeing, H.
Agricola
Right arrow Articles by Dierkes, J.
Right arrow Articles by Boeing, H.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS